October 27, 2016

Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that today it has requested approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1).  The trial is anticipated to provide important safety, tolerability and biomarker efficacy data for namacizumab to support differentiated clinical potential in fibrotic and metabolic disease.  As a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the inactive conformation of CB1, namacizumab has the potential to build on the significant historic mechanistic and clinical data on the modulation of CB1 in disease.
PDF Download

read more »

October 27, 2016

ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.
PDF Download - English Version
PDF Download - German Version

read more »

October 20, 2016

Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.
PDF Download

read more »

August 10, 2016

Evolva’s collaboration with US Navy to focus on resveratrol-based composites

Testing underway of materials fabricated from special formulation of Evolva’s resveratrol

Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of composites.
PDF Download - English Version
PDF Download - German Version

read more »

July 28, 2016

Cornelius and Evolva bring new fermented resveratrol to market

Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.
PDF Download - English Version
PDF Download - German Version

read more »

July 25, 2016

Evolva’s nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus

Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.
PDF Download - English Version
PDF Download - German Version

read more »

July 20, 2016

Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and expands its Scientific Advisory Board

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics.  The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.
PDF Download

read more »

May 26, 2016

Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides

Enabling patent key to the commercial expansion of and broader access to stevia sweeteners

Evolva (SIX: EVE) announces that the European Patent Office has granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived steviol glycosides.
PDF Download - English Version
PDF Download - German Version

read more »

May 17, 2016

Novimmune doubles down in HLH; second $31M round this year

Novimmune SA closed a CHF30 million (US$31 million) funding round, taking the total cash it has raised this year to CHF60 million and its lifetime total to more than CHF300 million.
PDF Download

read more »

April 11, 2016

Evolva to co-develop next-generation materials with US Navy

Applications include fire resistant coatings and structural materials for use in aircraft, waterborne craft, fabrics and construction

Evolva (SIX: EVE) announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential commercialisation of new lightweight, fire-resistant composite materials to save lives and reduce harm from fire.
PDF Download- English Version
PDF Download - German Version
 

read more »

April 05, 2016

Evolva gains exclusive license to develop and commercialise nootkatone globally for pest control

Evolva also signs broader nootkatone collaboration agreement with CDC

Evolva (SIX: EVE) announces that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control of a wide range of disease and virus vectors such as ticks, mosquitoes, fleas, flies, lice, bed bugs, and other biting insects.
PDF Download - English Version
PDF Download - German Version
 

read more »

March 11, 2016

Jean-Philippe Tripet speaks about the start-up scene in Switzerland

While Switzerland is very proud of its leading position in innovation ranking, a comparison with peer countries shows that we are poor in commercialising this excellent science (Gap 1).  Jean-Philippe Tripet CFA, to discuss Aravis' research showing that Switzerland invests 3 times less than Sweden and 6 times less than Israel in start-ups. With 200-300 start-ups per year, there is no deal flow issue. However, there is clear evidence that we significantly lack investment in new venture and small companies (Gap 2).
PDF Download

read more »

March 02, 2016

Evolva achieves milestones in flavour & fragrance alliance with Takasago

Evolva (SIX: EVE) today announces reaching the first technical milestones under the multi-year R&D alliance with Takasago. This achievement, taking place three months ahead of schedule, prompts a total milestone payment of CHF 1 million to Evolva.
PDF Download - English Version
PDF Download - German Version
 

read more »

February 17, 2016

Switzerland needs much more Venture investments

Unausgeschöpftes Potenzial -Obwohl die Schweiz eine der innovativsten Nationen weltweit ist, gibt es bei der Kommerzialisierung dieser Innovationen noch ziemlich viel Potenzial.

Obwohl die Schweiz eine der innovativsten Nationen weltweit ist, gibt es bei der Kommerzialisierung dieser Innovationen noch ziemlich viel Potenzial. Die Schweizer Pensionskassen investieren wenig in Start-ups. Dabei wäre Potenzial vorhanden.
PDF Download
 

read more »

February 16, 2016

Synaffix Announces Its Newly Constructed High Potency Lab Is Now Fully Operational

Synaffix BV, a biotechnology company exclusively focused on the development of an industry-leading antibody-drug  onjugate (ADC) technology, today announced that its newly constructed high potency
laboratory is now fully operational.
PDF Download

read more »

February 09, 2016

Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.

Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced its corporate name change from RuiYi, Inc. to Bird Rock Bio.
PDF Download

read more »

January 19, 2016

Aravis Biotech II: another exit

ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE

Acorda Therapeutics, Inc. ("Acorda") and Biotie Therapies Corp. ("Biotie" or the "Company") have today entered into a combination agreement ("Combination Agreement") whereby Acorda, either directly or through a wholly-owned subsidiary (jointly the "Offeror"), will make a public tender offer in Finland and in the United States to purchase all of the issued and outstanding shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie that are not owned by Biotie or any of its subsidiaries (the "Tender Offer").
PDF Download

read more »

January 19, 2016

Evolva clarifies key points in recent bank analyst note

Evolva (SIX: EVE) provides a clarification to Bank Vontobel’s analyst note of yesterday.

As previously reported, Evolva is in active discussions with Cargill regarding the optimal way to commercialise EverSweet™ and share the returns between Evolva and Cargill. These negotiations are being held in a positive and constructive manner.
PDF Download

read more »

January 11, 2016

Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders

Broad Participation from Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.
PDF Download

read more »

January 07, 2016

Synaffix Appoints World Leading Experts to Scientific Advisory Board and Recruits Chairman to Board of Directors

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced the appointment of a panel of industry experts to its inaugural scientific advisory board (SAB). Concurrent with the launch of the SAB, Synaffix has appointed Dr. Konstantinos Efthymiopoulos as the independent chairman of its Board of Directors.
PDF Download

read more »

January 05, 2016

ARAVIS terminates its energy activities

Aravis SA shut down its energy division as of 31 December 2015

Over the past six years, Aravis’ energy team has successfully invested in renewable energy assets across Europe. Investors in Aravis Energy I LP, a FINMA-regulated Swiss fund launched in 2009 and liquidated in 2015, received more than double of their commitments. The high return was attributable to the fund’s well differentiated build-and-sell strategy as well as the team’s ability to identify and exploit special situations, which enabled the fund to keep hold periods short and associated risks low. Besides Aravis Energy I LP, Aravis’ energy division has been accountable for a number of successful investments executed under advisory mandates.
PDF Download

read more »